Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Unknown 3Recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Breast Neoplasms 1774Neoplasms 1501Carcinoma, Non-Small-Cell Lung 1043Prostatic Neoplasms 957Colorectal Neoplasms 878Lung Neoplasms 800Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Leukemia, Myeloid, Acute 541Stomach Neoplasms 512Ovarian Neoplasms 507Neoplasm Metastasis 496Multiple Myeloma 495Recurrence 413Melanoma 386Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 355Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 305Endometrial Neoplasms 304Triple Negative Breast Neoplasms 299Glioblastoma 298Rectal Neoplasms 280Urinary Bladder Neoplasms 264Sarcoma 264Hematologic Neoplasms 264Colonic Neoplasms 254

Interventions

fludarabine phosphate 1Specimen Handling 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Prolymphocytic, B-Cell × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02863692 2025-12-08

CLL-Registry

German CLL Study Group

Recruiting
8,000 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡